文献速递浆细胞疾病

多发性骨髓瘤患者对COVID-19 mRNA疫苗接种的反应

Response to mRNA vaccination for COVID-19 among patients with multiple myeloma.
PubMed 文献 · Leukemia · 2021-07-29

本研究分析了103例多发性骨髓瘤(MM)患者对COVID-19 mRNA疫苗的血清抗体反应,发现活动期MM患者仅45%产生足够应答,22%为部分应答,且年龄、肾功能、淋巴细胞计数等因素与抗体水平相关。

要点

  • 活动期MM患者仅45%对mRNA疫苗产生足够抗体应答,22%为部分应答。
  • 冒烟型MM患者应答优于活动期患者。
  • 高龄、肾功能受损、淋巴细胞低、未达完全缓解等预测应答不佳。

核心结论

  • 多数多发性骨髓瘤患者对COVID-19 mRNA疫苗接种的应答受损。
  • 特定的临床和骨髓瘤相关特征可预测疫苗应答性。

研究设计与样本

  • 研究纳入103例多发性骨髓瘤患者(96例活动期,7例冒烟型),使用ELISA法检测SARS-CoV-2刺突蛋白IgG抗体。
  • 在免疫前及第一剂后12-21天、第二剂后14-21天检测血清抗体水平,疫苗为mRNA-1273或BNT162b2。

主要发现

  • 活动期MM患者中仅45%产生足够应答(>250 IU/mL),22%为部分应答(50-250 IU/mL)。
  • 冒烟型MM患者应答优于活动期患者。
  • 较低的刺突抗体水平与高龄、肾功能受损、低淋巴细胞计数、未受累免疫球蛋白水平降低、超过二线治疗及未达完全缓解相关。
  • 接种mRNA-1273疫苗的患者抗刺突抗体水平高于接种BNT162b2的患者。

关键数值与推荐

  • 应答分层标准:足够应答>250 IU/mL,部分应答50-250 IU/mL(高于COVID-19前背景),无应答<50 IU/mL。

临床怎么用

  • 临床应关注多发性骨髓瘤患者接种mRNA疫苗后的抗体应答,尤其是活动期、高龄、肾功能受损等高危因素患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response against SARS-CoV-2 is unknown. Thus, we analyzed responses to mRNA vaccination against COVID-19 among these patients. Using an ELISA-based assay that detects IgG antibodies to SARS-CoV-2 spike protein, we determined serum antibody levels prior to immunization and 12-21 and 14-21 days following the first and second vaccinations, respectively, with mRNA-1273 (Moderna) or BNT162b2 (Pfizer/BioNTech) among 103 MM patients (96 and 7 with active and smoldering disease, respectively). We stratified patients into clinically relevant responders (>250 IU/mL), partial responders (50-250 IU/mL, which was above pre-COVID-19 background), and nonresponders (<50 IU/mL). Smoldering MM patients responded better than those with active disease. Only 45% of active MM patients developed an adequate response, while 22% had a partial response. Lower spike antibody levels were associated with older age, impaired renal function, low lymphocyte counts, reduced uninvolved immunoglobulin levels, > second line of treatment, and among those not in complete remission. Patients who received mRNA-1273 vaccine had higher anti-spike antibody levels than those who were vaccinated with BNT162b2. Thus, most MM patients have impaired responses to mRNA vaccination against COVID-19, and specific clinical and myeloma-related characteristics predict vaccine responsiveness.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Stampfer SD, Goldwater MS, Jew S, et al. Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. Leukemia. 2021. PMID: 34326466. doi:10.1038/s41375-021-01354-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。